Armata Pharmaceuticals (ARMP) Depreciation & Amortization (CF) (2013 - 2026)
Armata Pharmaceuticals (ARMP) reported Depreciation & Amortization (CF) of $500000.0 for Q1 2026, up 32.63% on a YoY basis from $377000.0 in Q1 2025, and up 16.01% sequentially from $431000.0 in Q4 2025.
Armata Pharmaceuticals (ARMP) Depreciation & Amortization (CF) (2013 - 2026) Analysis & Trends
Armata Pharmaceuticals (ARMP) has 14 years of Depreciation & Amortization (CF) data on file, last reported at $500000.0 in Q1 2026.
- For the quarter ending Q1 2026, Depreciation & Amortization (CF) rose 32.63% year-over-year to $500000.0; the trailing twelve-month figure through Mar 2026 stood at $1.7 million (up 20.36% YoY), and the FY2025 full-year result was $1.5 million, up 15.55% from the prior year.
- Depreciation & Amortization (CF) climbed to $500000.0 in Q1 2026, from $431000.0 in the prior quarter.
- In the past five years, Depreciation & Amortization (CF) ranged from a high of $500000.0 in Q1 2026 to a low of $200000.0 in Q1 2022.
- A 5-year average of $305058.8 and a median of $313000.0 in 2024 frame the typical range for Depreciation & Amortization (CF).
- Across the five-year window, Depreciation & Amortization (CF) slumped 33.33% in 2022 and soared 41.63% in 2024, its largest moves.
- Tracing ARMP's Depreciation & Amortization (CF) over 5 years: stood at $245000.0 in 2022, then advanced by 19.59% to $293000.0 in 2023, then grew by 29.69% to $380000.0 in 2024, then increased by 13.42% to $431000.0 in 2025, then increased by 16.01% to $500000.0 in 2026.
- Business Quant data shows ARMP's Depreciation & Amortization (CF) at $500000.0 in Q1 2026, $431000.0 in Q4 2025, and $370000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Depreciation & Amortization (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | 196,658.72 |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 41.14 Mn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | 91,781.47 |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 55.90 Mn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 123.20 Mn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | 2.20 Mn |
| 10 | Armata Pharmaceuticals | 191.29 Mn | 186.49 Mn | - | 500,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 500,000.00 |
| Mar 31, 2026 | 500,000.00 |
| Dec 31, 2025 | 431,000.00 |
| Dec 31, 2025 | 431,000.00 |
| Sep 30, 2025 | 370,000.00 |
| Sep 30, 2025 | 370,000.00 |
| Jun 30, 2025 | 366,000.00 |
| Jun 30, 2025 | 366,000.00 |
| Mar 31, 2025 | 377,000.00 |
| Mar 31, 2025 | 377,000.00 |
| Dec 31, 2024 | 380,000.00 |
| Dec 31, 2024 | 380,000.00 |
| Sep 30, 2024 | 313,000.00 |
| Sep 30, 2024 | 313,000.00 |
| Jun 30, 2024 | 315,000.00 |
| Jun 30, 2024 | 315,000.00 |
| Mar 31, 2024 | 317,000.00 |
| Mar 31, 2024 | 317,000.00 |
| Dec 31, 2023 | 293,000.00 |
| Dec 31, 2023 | 293,000.00 |